ConductScience.org, home

Paper39957776

The 3 HP regimen for tuberculosis preventive treatment: safety, dosage and related concerns during its large-scale implementation in countries like India.

Bhargava A. Lancet Reg Health Southeast Asia, 2024. Cited by 12 papers, by iCite.

Cite this record

ConductScience Library. The 3 HP regimen for tuberculosis preventive treatment: safety, dosage and related concerns during its large-scale implementation in countries like India. Papers, record 39957776. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39957776

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The 3 HP regimen for tuberculosis preventive treatment: safety, dosage and related concerns during its large-scale implementation in countries like India.
PubMed
Journal
Lancet Reg Health Southeast Asia
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
12
iCite
Relative citation ratio, by iCite
2.85, provisional
iCite
Revised in PubMed
2025-02-18
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Bhargava AAnurag

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References46

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
136875946Pyridoxine in isoniazid-induced psychosis.Sudan J Paediatr2022https://conductscience.org/library/papers/36875946PubMed
238276634Uptake and Completion of Tuberculosis Preventive Treatment Using 12-Dose, Weekly Isoniazid-Rifapentine Regimen in Bangladesh: A Community-Based Implementation Study.Trop Med Infect Dis2023https://conductscience.org/library/papers/38276634PubMed
330954757Prevalence of vitamin deficiencies in an apparently healthy urban adult population: Assessed by subclinical status and dietary intakes.Nutrition2019https://conductscience.org/library/papers/30954757PubMed
432462048Seizures in an Immunocompetent Adult From Treatment of Latent Tuberculosis Infection: Is Isoniazid to Blame?Open Forum Infect Dis2020https://conductscience.org/library/papers/32462048PubMed
535849800How Flu-like Syndromes Contribute to Termination of Weekly Rifapentine-Based TB Preventive Therapy Is Still Poorly Predictable.Clin Infect Dis2022https://conductscience.org/library/papers/35849800PubMed
628574024N-acetyltransferase gene polymorphisms & plasma isoniazid concentrations in patients with tuberculosis.Indian J Med Res2017https://conductscience.org/library/papers/28574024PubMed
731605920Adverse event and treatment completion rates of a 12-dose weekly isoniazid and rifapentine course for South Korean healthcare workers.Respir Med2019https://conductscience.org/library/papers/31605920PubMed
829946528Pyridoxine for patients suffering from drug-susceptible tuberculosis in India.Public Health Action2018https://conductscience.org/library/papers/29946528PubMed
93775870Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide.Tubercle1986https://conductscience.org/library/papers/3775870PubMed
102152443Reversal of prolonged isoniazid-induced coma by pyridoxine.Arch Intern Med1990https://conductscience.org/library/papers/2152443PubMed
1122150035Three months of rifapentine and isoniazid for latent tuberculosis infection.N Engl J Med2011https://conductscience.org/library/papers/22150035PubMed
1225904367
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
Clin Infect Dis2015https://conductscience.org/library/papers/25904367PubMed
1319351215Study of NAT2 gene polymorphisms in an Indian population: association with plasma isoniazid concentration in a cohort of tuberculosis patients.Mol Diagn Ther2009https://conductscience.org/library/papers/19351215PubMed
1430361241Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study.Eur Respir J2018https://conductscience.org/library/papers/30361241PubMed
1533215187Impact of Age on Outcome of Rifapentine-Based Weekly Therapy for Latent Tuberculosis Infection.Clin Infect Dis2021https://conductscience.org/library/papers/33215187PubMed
162781610Severe 'flu'-like symptoms due to isoniazid--a report of three cases.Tubercle1989https://conductscience.org/library/papers/2781610PubMed
1729910114Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysis.Am J Prev Med2018https://conductscience.org/library/papers/29910114PubMed
1837567200
Nutritional supplementation to prevent tuberculosis incidence in household contacts of patients with pulmonary tuberculosis in India (RATIONS): a field-based, open-label, cluster-randomised, controlled trial.
Lancet2023https://conductscience.org/library/papers/37567200PubMed
1925337749High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.N Engl J Med2014https://conductscience.org/library/papers/25337749PubMed
206614636Undesirable side effects of isoniazid and rifampin in largely twice-weekly short-course chemotherapy for tuberculosis.Am Rev Respir Dis1983https://conductscience.org/library/papers/6614636PubMed

See all 46 referencesDownload CSV of references

Cited by9

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 12 citations.

PMIDTitleJournalYearIn PapersSource
42247627
A Novel Therapy With a One-Month Ultrashort Regimen to Halt Progression From Latent Infection to Active Tuberculosis Among Close Contacts (The TB‑YOUTH Study): Protocol for a Cluster Randomized Controlled Trial.
JMIR Res Protoc2026https://conductscience.org/library/papers/42247627PubMed
42237122Clinical effectiveness of three months once-weekly Isoniazid and Rifapentine regimen for treatment of Latent TB Infection: a systematic review and meta-analysis.BMC Infect Dis2026https://conductscience.org/library/papers/42237122PubMed
42154079Multidrug-resistant tuberculosis: a comprehensive review of pathogenesis, drug resistance, current treatment and future prospects.Arch Microbiol2026https://conductscience.org/library/papers/42154079PubMed
42020107Programmatic impact and cost-effectiveness of scaling up the short-course 3HP regimen for tuberculosis preventive treatment in Brazil.BMJ Glob Health2026https://conductscience.org/library/papers/42020107PubMed
41847763Implementation challenges of 3-month once-weekly rifapentine and isoniazid TB-preventive treatment in India.Int Health2026https://conductscience.org/library/papers/41847763PubMed
41732188Reappraising TB preventive treatment in India: programmatic and ethical implications of subclinical tuberculosis in household contacts.Lancet Reg Health Southeast Asia2026https://conductscience.org/library/papers/41732188PubMed
40326358Efficacy and safety of a novel short course rifapentine and isoniazid regimen for the preventive treatment of tuberculosis in Chinese silicosis patients: a pilot study (SCRIPT-TB).Emerg Microbes Infect2025https://conductscience.org/library/papers/40326358PubMed
40205610Advancement in diagnostic approaches for latent tuberculosis: distinguishing recent from remote infections.One Health Outlook2025https://conductscience.org/library/papers/40205610PubMed
40155893Treatment completion and safety profile of once-weekly 3HP regimen for tuberculosis preventive treatment in children and adolescents: a systematic review.BMC Infect Dis2025https://conductscience.org/library/papers/40155893PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39957776

GET https://conductscience.org/api/papers/v1/39957776/references?page=2